The National Health Product Administration of China has allowed the sale of a new strain of corona antiviral drug called Favilavir to market. An antimalarial drug has also been added to the treatment regimen of COVID-19 patients in China.

According to China Daily on February 17, this information was released on February 16 by the Taizhou city government of Zhejiang province.

A man recovered from COVID-19 disease donates plasma to scientists as a basis for research on treatment of the disease - Photo: REUTERS

Favilavir, previously known as Fapilavir, has been shown to be effective in treating patients with acute respiratory infections caused by a new strain of corona virus (COVID-19). This is the first new corona anti-virus drug product licensed to be manufactured in China.

Favilavir was developed by Zhejiang Hisun Pharmaceutical Company and is one of the three drugs that showed remarkable effectiveness in treatment, the Ministry of Science and Technology of China confirmed.

The first batch of drugs began production on February 16 and is expected to appear on the market soon, helping to prevent the disease and increase the rate of successful cure.

In other related developments, on February 17, Xinhua reported that a drug for malaria treatment will also be added to new guidelines for treating patients with corona virus infection based on clinical trial results. .

Speaking at a press conference on February 17, Ms. Sun Yanrong - deputy director of the Center for Biotechnology Development under the Ministry of Science and Technology of China - said that medical experts have agreed to give Chloroquine Phosphate. into the COVID-19 treatment regimen and will promptly introduce the drug to a wide clinical trial in the shortest time.

According to Ms. Sun Yanrong, Chloroquine Phosphate has been selected among tens of thousands of existing drugs and screened dozens of times before being tested. This is the drug to treat malaria that has been used for more than 70 years.

Ms. Sun Yanrong added that the drug is currently being used in 10 hospitals in Beijing, as well as in Guangdong and Hunan provinces of China.

The trial process with the participation of 100 patients and the group of patients treated with Chloroquine Phosphate had clear progress such as fever reduction, improved lung imaging ...

This group of patients also had a faster recovery time and did not have any apparent serious side effects from the drug.

Source: tuoitre.vn